ERLEADA
Total Payments
$54.6M
Transactions
106,961
Doctors
16,695
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $21.0M | 27,786 | 8,655 |
| 2023 | $13.0M | 26,016 | 7,910 |
| 2022 | $14.7M | 24,704 | 7,605 |
| 2021 | $3.5M | 18,816 | 5,997 |
| 2020 | $2.3M | 9,524 | 3,838 |
| 2019 | $9,269 | 115 | 108 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43.6M | 3,936 | 79.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.7M | 2,811 | 10.5% |
| Food and Beverage | $2.3M | 92,852 | 4.2% |
| Consulting Fee | $1.6M | 884 | 3.0% |
| Travel and Lodging | $839,977 | 2,507 | 1.5% |
| Education | $326,426 | 3,915 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $165,500 | 56 | 0.3% |
Payments by Type
Research
$43.6M
3,936 transactions
General
$11.0M
103,025 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | Janssen Research & Development, LLC | $10.0M | 0 |
| A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | Janssen Research & Development, LLC | $7.9M | 0 |
| A Phase 3 Study of Androgen Annihilation in High-risk Biochemically Relapsed Prostate Cancer | Janssen Research & Development, LLC | $4.3M | 0 |
| A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | Janssen Research & Development, LLC | $2.0M | 0 |
| Phase II trial of primary radiotherapy with androgen ablation with or without adjuvant niraparib for selected high risk local regional prostate cancer | Janssen Research & Development, LLC | $1.8M | 0 |
| A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases | Janssen Research & Development, LLC | $1.4M | 0 |
| Chen_Incorporating apalutamide + AAP and advanced imaging into salvage treatment for patients with node positive prostate cancer after radical prostatectomy | Janssen Research & Development, LLC | $1.4M | 0 |
| Parallel Phase III Randomized Trials for High Risk Prostate Cancer EVALUATING De-Intensification for Lower Genomic Risk and Intensification OF CONCURRENT THERAPY for Higher Genomic Risk WITH RADIATION (PREDICT-RT*) | Janssen Research & Development, LLC | $1.2M | 0 |
| A randomized Phase III study Conventional Androgen Deprivation Therapy with or without Abiraterone acetate + prednisone and Apalutamide following a detectable PSA After Radiation and Androgen Deprivation Therapy A randomized Clinical Trial in Men with High Risk Prostate Cancer | Janssen Research & Development, LLC | $1.2M | 0 |
| Scher_Metacure: Multi-arm Multi-modality Therapy for very high risk localized and low volume prostatic adenocarcinoma | Janssen Research & Development, LLC | $1.2M | 0 |
| A Single-Dose, Open-label, Randomized, 2-Part Pivotal Study to Assess Bioequivalence of a New Apalutamide Film-Coated Tablet with Respect to Current Commercial Film-Coated Tablets and Food Effect of the New Tablet in Healthy Male Participants | Janssen Research & Development, LLC | $1.1M | 0 |
| Randomized Phase II Study of Salvage XRT + ADT + Abiraterone Acetate and Apalutamide ARN509 for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide Abiraterone Acetate and Apalutamide FORMULA509 Trial | Janssen Research & Development, LLC | $991,066 | 0 |
| A Randomized Double blind Placebo controlled Phase 3 Study of JNJ56021927 in Subjects with High risk Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | Janssen Research & Development, LLC | $930,923 | 0 |
| Phase II Course Determining Study for Men with Hormone Naive Metastatic Prostate Cancer | Janssen Research & Development, LLC | $749,261 | 0 |
| A randomized Phase III study Conventional Androgen Deprivation Therapy with or without Abiraterone acetate + prednisone and Apalutamide following a detectable PSA After Radiation and Androgen Deprivation Therapy A randomized Clinical Trial in Men with H | Janssen Research & Development, LLC | $608,023 | 0 |
| A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function | Janssen Research & Development, LLC | $545,810 | 0 |
| A randomized Phase III study Conventional Androgen Deprivation Therapy with or without Abiraterone acetate + prednisone and Apalutamide following a detectable PSA After Radiation and Androgen Deprivation Therapy A randomized Clinical Trial in Men with High Risk Prostate Cancer | Janssen Research & Development, LLC | $522,381 | 0 |
| A Phase II Double Blinded Placebo Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti Androgen Therapy with Apalutamide in Recurrent Prostate Cancer | Janssen Research & Development, LLC | $398,347 | 0 |
| A Randomized Phase II Study of Apalutamide + Stereotactic Body Radiotherapy SBRT In Castration Resistant Prostate Cancer Patients with Oligometastatic Disease on PSMAPET Imaging | Janssen Research & Development, LLC | $376,737 | 0 |
| Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*) | Janssen Research & Development, LLC | $363,951 | 0 |
Top Doctors Receiving Payments for ERLEADA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Urology | West Hollywood, CA | $57,927 | 9 |
| , MD | Urology | Los Angeles, CA | $57,780 | 81 |
| , MD | Urology | Wichita, KS | $54,762 | 105 |
| , M.D | Urology | Roseville, CA | $54,647 | 62 |
| , M.D | Urology | Sacramento, CA | $51,407 | 45 |
| , DO,PHARMD | Medical Oncology | Dallas, TX | $50,389 | 38 |
| , NP | Urology | Los Angeles, CA | $50,225 | 105 |
| , MD | Urology | Aurora, CO | $48,886 | 48 |
| , M.D | Urology | San Antonio, TX | $48,213 | 98 |
| , MD | Radiation Oncology | Panama City, FL | $47,916 | 78 |
| , M.D | Urology | Shreveport, LA | $47,050 | 67 |
| , MD | Internal Medicine | Santa Monica, CA | $46,344 | 64 |
| , M.D | Hematology & Oncology | Milwaukee, WI | $45,721 | 40 |
| , CRNP | Family | Philadelphia, PA | $45,640 | 82 |
| , MD | Urology | Bryn Mawr, PA | $44,527 | 70 |
| , MD | Urology | Poughkeepsie, NY | $44,323 | 75 |
| , M.D | Hematology & Oncology | Albany, NY | $41,456 | 37 |
| , MD | Urology | Cayey, PR | $40,565 | 49 |
| , MD | Urology | West Bloomfield, MI | $40,465 | 66 |
| , M. D | Hematology & Oncology | Franklin, WI | $40,314 | 34 |
| , M.D | Hospitalist | New Orleans, LA | $39,265 | 41 |
| , MD | Urology | Libertyville, IL | $38,279 | 96 |
| , PA-C | Medical | Baltimore, MD | $38,227 | 126 |
| , MD | Hematology & Oncology | Las Vegas, NV | $38,124 | 49 |
| , MD | Urology | Elmont, NY | $38,116 | 78 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $44.0M
- Janssen Biotech, Inc. $9.6M
- Janssen Scientific Affairs, LLC $640,311
- Janssen Global Services, LLC $223,621
- Janssen Pharmaceuticals, Inc $148,251
- Johnson & Johnson Health Care Systems Inc. $6,091
Product Information
- Type Drug
- Total Payments $54.6M
- Total Doctors 16,695
- Transactions 106,961
About ERLEADA
ERLEADA is a drug associated with $54.6M in payments to 16,695 healthcare providers, recorded across 106,961 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2019 to 2024. In 2024, $21.0M was paid across 27,786 transactions to 8,655 doctors.
The most common payment nature for ERLEADA is "Unspecified" ($43.6M, 79.9% of total).
ERLEADA is associated with 20 research studies, including "A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy" ($10.0M).